BLATOPICALOINTMENT
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 28m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANTYL is a topical collagenase ointment indicated for debriding necrotic tissue in wounds such as severe burns, diabetic ulcers, and pressure ulcers. It works by enzymatically breaking down denatured collagen in eschar and necrotic tissue, facilitating autolytic debridement without harming healthy tissue. This enzyme-based mechanism allows selective removal of dead tissue while preserving viable wound bed.
$195MPart D
LOE ApproachingAs a legacy product approaching LOE with stable $195M Part D spending, the brand team is likely focused on market defense and operational efficiency rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Medihoney and Santyl for Burn Injuries
Started Mar 2014
21 enrolled
Burns
Why This Matters for Your Career
Smith and Nephew is hiring 10 roles related to this product
Worked on SANTYL at Smith and Nephew? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.